results obtained by the three methods were subjected to a comparative evaluation.
Introduction
Pseudomonas aeruginosa and other Pseudomonas spp. continue to be a significant cause of morbidity and mortality, especially in intensive care units, and they are frequent isolates causing nosocomial epidemics. [1] [2] [3] [4] [5] [6] The multiresistance of these isolates plays an important role in the colonization or infection of chronically hospitalized patients. 2, [6] [7] [8] For effective treatment of nosocomial infections caused by these multiresistant isolates, clinicians often have to resort to the most potent fluoroquinolones or combinations of different antibiotics. 6, 7, 9, 10 The most widely documented synergy is to be found when -lactams are combined with aminoglycosides. These combinations are synergic against most species, including P. aeruginosa. Although these combinations are clinically well proven to provide effective treatment, there are limitations, such as an increasing resistance of Pseudomonas spp. to -lactam antibiotics and toxicity associated with aminoglycoside therapy. 11 For this reason, there is a continuous search for alternative combinations. One such group of combinations is fluorinated quinolones with -lactams, where synergy has been demonstrated against clinical isolates of P. aeruginosa. 11 Various in-vitro methods are available for measurement of the synergic effects of combinations of antibiotics, but the results may exhibit discrepancies when different tests are used. [12] [13] [14] [15] In the present study, three methods (disc diffusion, 'chequerboard' titration and the time-killing method) were used to detect synergy of selected antibiotics (aminoglycosides, fluoroquinolones and third-generation cephalosporins) against clinical isolates of Pseudomonas spp. The 
Investigation

Materials and methods
The 18 Pseudomonas sp. isolates used in this study were isolated from severe infections in different patients from different clinics. Routine isolation and identification methods were applied. 13 These isolates belonged in different Pseudomonas spp. and their antibiotic sensitivities to aminoglycosides, fluoroquinolones and third-generation cephalosporins were also different.
The minimum inhibitory concentrations (MICs) of the antibiotics were determined in Mueller-Hinton broth with the microbroth dilution method. 12 The range of antibiotic dilutions was 0.031-512 mg/L.
The synergic effects of the antibiotic combinations against the selected isolates were examined by three methods: (i) disc diffusion test-two discs, each containing one or other of the two tested antibiotics, were placed at a distance of about 20 mm from each other on top of a Pseudomonas sp. isolate-covered agar plate. Synergy was considered to occur when there was a well-observed change (у2 mm) in the zone of inhibition. The synergy was classified as weak when a change of Ͻ2 mm was observed in the zone of inhibition. 12, 16 (ii) 'Chequerboard' titrationsubcultures of the bacteria were made from fresh blood agar and incubated overnight at 37°C in Mueller-Hinton broth. Two-fold dilutions of the antibiotics were made and 50 L aliquots were placed into the wells of a sterile plastic microtitre plate. The criterion of synergy was an FIC index not higher than 0.5. 12 The ranges of antibiotic dilutions used in the 'chequerboard' titration were: 0.5-512 mg/L for aminoglycosides, 0.031-64 mg/L for quinolones and 0.5-256 mg/L for cephalosporins. (iii) Time-killing method -subcultures of the test bacteria were made from fresh blood agar culture in Mueller-Hinton broth and were incubated overnight. The same inoculum was used in fresh Mueller-Hinton broth containing no antibiotic, one or other of the antibiotics in ½ ϫ MIC concentrations, or the same amounts of antibiotics in combination, and the cultures were incubated for 24 h at 37°C. The cfu/mL values of the cultures were determined at the beginning of the incubation and after 2, 4, 6 and 24 h of incubation. Synergy was defined as a у100-fold increase in killing at 24 h (as measured by colony counts) with the combination in comparison with the more active single drug. 12, 17 The following antimicrobial agents were used: amikacin (Bristol Myers Squibb, Sermoneta, Italy), netilmicin (Schering-Plough Labo N.V., Heist-op-den-Berg, Belgium), ciprofloxacin (Bayer, Leverkusen, Switzerland), ofloxacin (Hoechst AG, Frankfurt am Main, Germany), pefloxacin (Rhône-Poulenc/EGIS Gyógyszergyár, Budapest, Hungary), cefoperazone (Pfizer Biogál Kft., Debrecen, Hungary), ceftazidime (Glaxo S.P.A., Verona, Italy) and ceftriaxone (Hoffmann-La Roche Ltd, Basel, Switzerland). The stock solutions were prepared in sterile distilled water.
Results
Eighteen isolates belonging to various Pseudomonas spp. with different resistance patterns were used for this study. The MICs of the tested antibiotics were determined (Table  I) . According to the resistance breakpoints, on the basis of the NCCLS performance standards, 18 2-12 isolates were resistant to the tested individual antibiotics. Ceftazidime, amikacin and ciprofloxacin proved to be the most active agents in the different groups of antibiotics against these isolates. The P. aeruginosa isolates were more sensitive to aminoglycosides, ceftazidime and fluoroquinolones than the isolates of the other species. Table II relates to the evaluation of the frequency of the synergic effects of the antibiotic combinations tested by the disc diffusion method. Amikacin and netilmicin in combination with cefoperazone, ceftriaxone and ceftazidime exhibited a synergic effect (expressed or weak) in the case of 7-12 of the isolates, although ceftriaxone is not an everyday antipseudomonal antibiotic. When the combinations of ciprofloxacin, ofloxacin and pefloxacin with ceftazidime were tested by this method, synergy was observed for only 3-5 isolates.
Somewhat different results were obtained when 'chequerboard' titration was used (Table III) . The combination of amikacin with ceftriaxone exerted a synergic effect against seven isolates, whereas that of netilmicin with cefoperazone did so against six of the 18 Pseudomonas spp. isolates. The other combinations displayed synergic effects against fewer than six of the tested isolates. For some isolates and antibiotic combinations, only an additive effect was indicated by 'chequerboard' titration, whereas the disc diffusion method revealed weak synergy. Synergy was found in 61 cases by disc diffusion, but only in 37 cases with 'chequerboard' titration. The antibiotic combinations amikacin-ceftriaxone and netilmicin-cefoperazone exhibited the best synergic effect with both of these methods. No antagonism was detected with disc diffusion and 'chequerboard' titration for any of the combinations used.
The FIC indices for the different antibiotic combinations are shown in Table IV for six Pseudomonas spp. isolates belonging to different species, which were selected according to their different sensitivities to the tested antimicrobials (Table I) 
Discussion
Despite the recent introduction into clinical practice of highly potent antibiotics such as the newer aminoglycosides, fluoroquinolones and the third-generation cephalosporins or imipenem, Pseudomonas spp. infections (involving mostly nosocomial multiresistant isolates) pose a major therapeutic problem for clinicians world-wide. The application of antimicrobial combination therapy in such patients attempts to take advantage of synergic antibiotic interactions to enhance the efficacy in the treatment of the infections and to decrease the risk of development of resistance during therapy. Combinations of aminoglycosides and antipseudomonal penicillins have been well investigated. 17, 19, 20 Weiss & Lapointe 19 reported that a tobramycin-ceftazidime combination exerted a synergic effect against 39% of the tested P.aeruginosa isolates from patients with cystic fibrosis. Jenkins & Lewis, 8 however, found no significant in-vitro synergy between fluoroquinolones and other antimicrobial agents when they applied the 'chequerboard' titration method against Pseudomonas (Burkholderia) cepacia isolates. Moody et al. (1987) , 21 using the same method, demonstrated synergy for various Pseudomonas spp. when ciprofloxacin was administered in combination with different -lactam antibiotics. Enciso 22 found that ceftazidime in combination with ciprofloxacin exhibited synergy against 40% of P. aeruginosa isolates, whereas ceftazidime plus amikacin did so against 53% of the isolates. Gould & Milne 11 tested the efficacies of gentamicin and ciprofloxacin in combination with piperacillin-tazobactam against different Grampositive and Gram-negative species, including Pseudomonas spp. isolates, and described a synergic effect. Neu 9, 10, 23 observed synergy when quinolones and antipseudomonal penicillins and ceftazidime were applied in combination. His results led him to suggest the use of these combinations in therapy in special cases. 9, 10, 23 The aim of the present study was to evaluate the effects of different aminoglycoside, fluoroquinolone and -lactam combinations against selected Pseudomonas spp. exhibiting different resistance patterns to these drugs. An evaluation of the synergic effects of different antibiotic combinations is highly dependent on the method used. 24 Different methods were applied during this study and the results were compared. Although 7-12 of 18 isolates displayed expressed or weak synergy by the disc diffusion screening test when amikacin or netilmicin and thirdgeneration cephalosporins were applied, only 2-7 isolates did so when combinations of fluoroquinolones were tested. With the 'chequerboard' titration method and calculation of the FIC index, a synergic effect (FIC index р0.5) was observed less frequently. In our experience, the changes in the zone of inhibition can reveal synergy where 'chequerboard' titration and the time-killing method do not. Different combinations of the aminoglycosides-fluoroquinolones and third-generation cephalosporins exhibited different effects, depending on the Pseudomonas spp. isolates and the antibiotic combination. Discrepancies were observed between the FIC indices and the killing activities resulting from time-killing experiments. The combination of amikacin and ceftriaxone exerted synergic killing activity after 6 and 24 h for ten isolates where 'chequerboard' titration did not indicate a synergic effect. In contrast, 'chequerboard' titration indicated synergy for six isolates where the time-killing method did not. Differences were likewise observed between the disc diffusion and time-killing methods (data not shown). Haller 24 tested the effects of combinations of ciprofloxacin and aminoglycosides against Escherichia coli, Serratia marcescens and Pseudomonas spp. isolates, and his results appear to demonstrate methodology-based differences in the in-vitro activities of these combinations. His study revealed less than 5% synergy for ciprofloxacin plus azlocillin and less than 1% synergy for the ciprofloxacin plus aminoglycoside combination against P. aeruginosa isolates. On the other hand, Chin et al. 25 detected synergy and/or an additive beneficial effect against 78% of P. aeruginosa when ciprofloxacin was combined with azlocillin.
In the present study, the fluoroquinolone ciprofloxacin in combination with third-generation cephalosporins had the highest activity. However, all combinations used exerted a synergic effect against some of the 18 P s e u d omonas spp. isolates belonging to the different species and selected on the basis of their different resistance patterns.
In conclusion, these in-vitro comparative studies demonstrate that, besides the well-known synergic effects of aminoglycoside and -lactam antibiotics, quinolones (primarily ciprofloxacin) in combination with ceftazidime may exert enhanced activity against clinical isolates of Pseudomonas spp. However, our data suggest that measurement of the time-killing of the bacteria is the most reliable means of assessing the existence of a synergic effect.
